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S U M M A R Y
Objectives: Few studies have investigated serum levels of platelet-derived growth factor (PDGF) in
patients with chronic hepatitis B (CHB). The present study aimed to determine whether PDGF-BB could
serve as a potential biomarker for the detection of liver ﬁbrosis.
Methods: From October 2013 to August 2015, 465 patients with CHB were enrolled prospectively in this
study. All patients underwent liver biopsy and staging based on the Ishak system. The serum PDGF-BB
level was measured quantitatively by ELISA.
Results: The serum PDGF-BB level was negatively correlated with ﬁbrosis stage in all patients (p = 0.003,
Spearman’s rho = 0.16) and was signiﬁcantly different between ﬁbrosis stages. The areas under the
receiver operating characteristics curves (AUROCs) for serum PDGF-BB level and PGT score (a
combination of PDGF-BB, gamma-glutamyl transpeptidase, and platelet levels) were 0.667 and 0.831,
respectively, for patients with signiﬁcant ﬁbrosis and normal alanine aminotransferase (ALT) levels. The
AUROCs for aspartate aminotransferase-to-platelet ratio (APRI) and ﬁbrosis index based on four factors
(FIB-4) were 0.823 and 0.821, respectively. Importantly, a cut-off value of 1.05 and 1.43, respectively,
resulted in a sensitivity of 0.95 and 0.52, a speciﬁcity of 0.29 and 0.95, a positive predictive value of
0.30 and 0.79, and a negative predictive value of 0.96 and 0.86. The rate of correct diagnosis was up to
88.4% when using cut-offs of 1.05 and 1.43 for the absence or presence of signiﬁcant ﬁbrosis,
respectively.
Conclusions: Serum PDGF-BB decreased remarkably as ﬁbrosis progressed, and this could be used as a
non-invasive biomarker for the assessment of ﬁbrosis stage in patients with CHB.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hepatitis B virus (HBV) infection remains a major global health
concern. Approximately 240 million individuals are chronically
infected with HBV worldwide, and 650 000 people die annually
from HBV-related cirrhosis, hepatocellular carcinoma (HCC), and* Corresponding authors.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).liver failure.1,2 China has the world’s largest burden of HBV
infection, with an estimated 120 million people carrying hepatitis
B surface antigen (HBsAg) and nearly 300 000 deaths from HBV-
related liver disease each year.3 Therefore, the assessment of liver
pathology is very important clinically, as it identiﬁes those patients
who are most likely to beneﬁt from therapeutic strategies.4
To date, percutaneous liver biopsy followed by histological
analysis remains the main technique for evaluating the severity of
liver injury. However, the clinical use of this diagnostic technique
is limited by the invasiveness of the procedure and its associated
drawbacks, including pain, bleeding, and sampling error.5,6
Recently, several non-invasive methods and scoring models have
been developed to assess liver damage.7 Among these, theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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and ﬁbrosis index based on four factors (FIB-4) have become the
two most commonly used scoring methods; these were initially
used to evaluate patients with chronic hepatitis C virus (HCV)
infection.8 A number of studies have indicated that APRI and FIB-4
are also appropriate markers for detecting liver ﬁbrosis in patients
with chronic hepatitis B (CHB) infection.9,10 Furthermore, the most
recent study to date, reported by the present study group, has
established a ﬁbrosis index (ﬁb-index) for the assessment of liver
ﬁbrosis based on panels of selected cytokines.11 Compared with
APRI and FIB-4 scores, this ﬁb-index showed greater diagnostic
performance in identifying signiﬁcant ﬁbrosis in patients with
mildly elevated alanine aminotransferase (ALT) levels.
It has been established that, in addition to cytokines, growth
factors and other locally produced mediators govern the progres-
sion from chronic liver injury to ﬁbrosis, cirrhosis, and eventually
tumor formation. Platelet-derived growth factor (PDGF) belongs to
a family of growth factors that were originally identiﬁed as key
mediators of vascular pathologies.12 Several recent studies have
indicated that PDGF, one of the most potent known mitogens,
promotes liver ﬁbrosis by activating hepatic stellate cells (HSCs).
Furthermore, PDGF is overexpressed in liver tissue during
ﬁbrogenesis.13–15 However, few studies have investigated serum
levels of PDGF in patients with liver ﬁbrosis.
The aims of the current study were to evaluate the association
between serum PDGF-BB level and histological liver damage in a
large cohort, and to assess the diagnostic value of PDGF as a
biomarker of liver ﬁbrosis in patients with CHB.
2. Methods
2.1. Patients
From October 2013 to August 2015, 489 consecutive patients
with CHB who underwent liver biopsy in 24 teaching hospitals
located in mainland China were recruited into this study. Patients
were included in the study if they met the following criteria: (1)
HBsAg-positive for at least 6 months, (2) treatment-naı¨ve, (3) aged
between 18 and 65 years, (4) serum negative for anti-hepatitis A
virus (HAV) IgM, anti-HCV, anti-hepatitis E virus (HEV) IgM/IgG,
anti-Epstein–Barr virus (EBV) IgM, and anti-cytomegalovirus
(CMV) IgM, and (5) no use of potential transaminase-lowering
agents such as bicyclol for at least 2 weeks prior to blood sampling
biochemistries. The exclusion criteria for this study encompassed
overlapping etiologies for hepatitis, including HCV, hepatitis D
virus (HDV), human immunodeﬁciency virus (HIV), alcoholism,
autoimmune disease, genetic conditions, drug-induced liver
disease, non-alcoholic fatty liver disease, and other chronic liver
diseases. Patients with decompensated cirrhosis or HCC were also
excluded.
All patients provided written informed consent for the scientiﬁc
use of their clinical data and samples, and the study was approved
by the local ethics committee of Peking University First Hospital.
The complete protocol for the clinical trial has been registered at
clinicaltrials.gov (NCT01962155) and chictr.org (ChiCTR-DDT-
13003724).
2.2. Liver pathology
Ultrasonography-guided liver biopsies measuring 2.0 cm
were routinely performed at each hospital according to a
standardized protocol after receiving the patient’s written
informed consent. Pathological interpretations were conducted
in the Department of Pathology at Youan Hospital, which is
afﬁliated with the Capital Medical University. Each section was
assessed independently and in a blinded fashion by twopathologists. When discrepancies in these assessments occurred,
the samples were reviewed by experienced pathologists, who were
also responsible for reassessing a random selection of 10% of the
samples. Fibrosis was staged according to the Ishak ﬁbrosis score,
and a score of F3 was considered signiﬁcant ﬁbrosis.8,16
2.3. Examination of virological markers
Qualitative assessments of hepatitis B e antigen (HBeAg) and
hepatitis B e antibody (HBeAb) levels were performed using
relevant Roche Elecsys assays (Roche Diagnostics, Penzberg,
Germany). Serum HBV DNA levels (range 2.0  101 to
1.7  108 IU/ml) were measured using a COBAS AmpliPrep/COBAS
TaqMan method, as described previously.17
2.4. Determination of serum PDGF-BB level
The serum PDGF-BB level was determined using an ELISA (R&D,
Minneapolis, MN, USA), according to the manufacturer’s instruc-
tions.
2.5. APRI and FIB-4 scores
APRI and FIB-4 scores were calculated using the following
formulas: APRI = (AST/upper limit of normal/PLT count (109/
l))  100; FIB-4 = (age  AST)/(PLT count (109/l)  ALT1/2).
2.6. Statistical analysis
All statistical analyses were performed using SPSS v.16.0
software (SPSS Inc., Chicago, IL, USA). Quantitative variables were
expressed as the mean  standard deviation (SD). The Chi-square
test was used to analyze relationships between categorical variables.
The Student t-test, Kruskal–Wallis test, and Mann–Whitney U-test
were used to analyze differences in normally and non-normally
distributed variables between the groups. Spearman’s rank tests were
used to analyze associations between different variables and ﬁbrosis
stages. Multiple ordered analysis among variables was performed to
derive independent related factors of ﬁbrosis stages, and an algorithm
for signiﬁcant ﬁbrosis was chosen. Another algorithm of parameters
for signiﬁcant ﬁbrosis was also derived from logistic linear analysis.
The diagnostic abilities of different variables were evaluated based on
estimated areas under the receiver operating characteristics curve
(AUROCs) and by calculations of the sensitivity, speciﬁcity, positive
predictive value (PPV), and negative predictive value (NPV) of
different cut-off points. Statistical signiﬁcance was deﬁned as
p < 0.05 (two-tailed).
3. Results
3.1. Patient characteristics
A total of 489 patients were enrolled in this study; 24 patients
were excluded (21 patients had no biopsy data and three patients
had missing clinical data). The remaining 465 cases were analyzed,
including 235 patients from the previous study by this group of
authors.11 Baseline characteristics of the study patients are
summarized in Table 1.
3.2. Serum PDGF-BB decreased in parallel with ﬁbrosis progression
Serum PDGF-BB was detected using ELISA kits. In the total CHB
patient sample, the measured serum PDGF-BB levels differed
signiﬁcantly between ﬁbrosis stages (F2 vs. F3, p = 0.008; F2 vs. F4,
p = 0.0001; F2 vs. F5–6, p = 0.008; F3 vs. F5–6, p = 0.001; F4 vs. F5–
6, p = 0.003) (Figure 1A). In the group of CHB patients with normal
Table 1
Patient characteristicsa
Parameters Total (n = 465) ALT < ULN (n = 122) ALT ULN (n = 343) p-Valueb
Age 30 years 97 (20.9%) 23 (18.9%) 74 (21.6%) 0.31
Sex, male 363 (78.1%) 89 (73.0%) 274 (79.9%) 0.073
BMI, kg/m2 23.35  3.39 22.90  2.76 23.52  3.58 0.17
PDGF-BB, log10 pg/ml 4.75  0.40 4.70  0.40 4.77  0.39 0.057
HBV DNA, log10 IU/ml 6.31  1.89 5.74  2.13 6.52  1.759 <0.001
Platelet count, 109/l 173.51  53.68 176.13  51.93 172.57  58.35 0.54
AST, U/l 68.82  90.15 26.06  7.97 84.17  100.68 <0.001
ALP, U/l 84.11  28.71 74.45  22.93 87.58  29.80 <0.001
GGT, U/l 57.33  63.59 32.00  34.08 66.42  69.07 <0.001
TBil, mmol/l 16.93  15.72 14.50  7.72 17.80  17.67 0.009
Albumin, g/l 44.25  5.36 44.63  4.17 44.11  5.72 0.283
PT, s 13.36  6.77 12.78  1.57 13.58  7.84 0.263
INR 1.14  1.52 1.03  0.09 1.19  1.80 0.15
Fibrosis stage 0.001
F0–1 148 (31.8%) 57 (46.7%) 91 (26.5%)
F2 150 (32.3%) 33 (27.0%) 117 (34.1%)
F3 90 (19.4%) 17 (13.9%) 73 (21.3%)
F4 64 (13.8%) 14 (11.5%) 50 (14.6%)
F5 13 (2.8%) 1 (0.85) 12 (3.5%)
ALT, alanine aminotransferase; ULN, upper limit of normal; BMI, body mass index; PDGF-BB, platelet-derived growth factor BB; HBV, hepatitis B virus; AST, aspartate
aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; TBil, total bilirubin; PT, prothrombin time; INR; international normalized ratio.
a Results are presented as the mean  standard deviation, or n (%).
b Between patients with ALT <ULN (n = 122) and ALT ULN (n = 343).
Figure 1. Serum platelet-derived growth factor BB (PDGF-BB) level correlated with histological ﬁbrosis stages in (A) all chronic hepatitis B patients, and (B) chronic hepatitis B
patients with normal alanine aminotransferase (ALT). Median values with the 95% conﬁdence interval (of the median) are presented.
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BB levels than the patients with no signiﬁcant ﬁbrosis (F0–2 vs. F3–
6, p = 0.0008) (Figure 1B). Spearman’s rank test results showed that
the serum PDGF-BB level was negatively correlated with ﬁbrosis
stage (p = 0.003, r = 0.16) in all patients. Correlational analyses
indicated that the serum PDGF-BB level was clearly correlated with
age (p = 0.002, r = 0.007) and PLT count (p < 0001, r = 0.028) in
both groups (Table 2).
3.3. Associations between PDGF-BB, routine parameters, and ﬁbrosis
stages
Univariate analysis showed that the parameters age, ALT, AST,
alkaline phosphatase (ALP), gamma-glutamyl transpeptidase
(GGT), and total bilirubin were positively associated with ﬁbrosis
stage, while PLT count, albumin, HBV DNA, and PDGF-BB were
negatively associated with ﬁbrosis stage (Table 3). Multiple
ordered logistic regression analysis was then performed with
the Ishak ﬁbrosis score as the dependent variable, F4 as the
reference category, and all parameters above as the explanatory
variables. This indicated that PDGF-BB, GGT, and PLT count were
independent factors of liver ﬁbrosis stage (Table 4). The presence of
signiﬁcant ﬁbrosis (F3) is usually used as a determinant forinitiating antiviral therapy; the algorithm of independent factors
for signiﬁcant ﬁbrosis was chosen.
3.4. Diagnostic value of serum PDGF-BB and other models in liver
ﬁbrosis
The diagnostic value of serum PDGF-BB in predicting liver
ﬁbrosis was further assessed using AUROC analysis. The AUROCs of
serum PDGF-BB were 0.560 (95% conﬁdence interval (CI) 0.502–
0.617) for F2, 0.609 (95% CI 0.556–0.662) for F3, and 0.574 (95%
CI 0.505–0.644) for F4 in the total cohort of CHB patients. These
ﬁndings are shown in Table 5. Additionally, the algorithms by
multiple ordered logistic regression analysis showed AUROCs of
0.675 (95% CI 0.623–0.728) for F2, 0.705 (95% CI 0.665–0.756) for
F3, and 0.739 (95% CI 0.681–0.798) for F4 (these data are not
shown).
To improve the diagnostic performance of serum PDGF-BB,
logistic linear analysis was also performed combining PDGF-BB,
GGT, and PLT levels, i.e., the PGT; distinct increases in the resulting
AUROCs were found, which became 0.711 (95% CI 0.661–0.761) for
F2, 0.746 (95% CI 0.699–0.793) for F3, and 0.755 (95% CI 0.699–
0.812) for F4. Furthermore, existing APRI and FIB-4 scores were
compared against the PGT score, and they produced similar results
Table 2
Associations between serum PDGF-BB levels and routine parameters
PDGF-BB vs. Total CHB patients CHB patients with
ALT <ULN
r/rho p-Value r/rho p-Value
Age (<30, 30) 0.144 0.002a 0.242 0.007a
Sex (female, male) 0.038 0.417 0.153 0.092
BMI, kg/m2 0.023 0.618 0.019 0.833
ALT, U/l 0.011 0.815 0.12 0.188
AST, U/l 0.01 0.833 0.065 0.479
ALP, U/l 0.001 0.98 0.039 0.687
GGT, U/l 0.034 0.466 0.03 0.744
Albumin, g/l 0.021 0.656 0.07 0.448
TBil, mmol/l 0.053 0.258 0.087 0.345
Platelet count, 109/l 0.224 <0.001a 0.2 0.028a
HBV DNA, IU/ml 0.052 0.264 0.145 0.111
Fibrosis stage
F0–1, F2, F3, F4, F5 0.16 0.003
F0–2, F3 0.25 0.0058
PDGF-BB, platelet-derived growth factor BB; CHB, chronic hepatitis B; ALT, alanine
aminotransferase; ULN, upper limit of normal; BMI, body mass index; AST,
aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl
transpeptidase; TBil, total bilirubin; HBV, hepatitis B virus.
a Signiﬁcant.
J. Zhou et al. / International Journal of Infectious Diseases 49 (2016) 94–99 97for the AUROCs. The PGT score was calculated using the formula:
PGT = 1.951 – (0.003  PLT) + (0.004  GGT) – (0.072  logPDGF-
BB).
3.5. Diagnostic value of the PGT score for patients with normal ALT
For the 122 patients with normal ALT, the AUROC of the PGT
score for F2 was 0.756, whereas it was 0.831 for F3 and 0.877 for
F4. In comparison to the existing scores, the PGT score showedTable 3
Associations between PDGF-BB, routine parameters, and ﬁbrosis stages—univariate ana
Parameters F0–1 F2 
Age 30 years 49 (33.1%) 28 (18.7%) 
Sex, male 114 (77.0%) 117 (78.0%) 
BMI, kg/m2 22.83  2.48 23.47  4.43 
ALT, U/l 73.43  85.02 122.68  142.35 
AST, U/l 43.93  40.78 73.87  79.26 
ALP, U/l 78.71  25.30 79.74  24.95 
GGT, U/l 35.75  40.03 54.97  64.12 
Albumin, g/l 45.42  5.24 44.56  4.50 
TBil, mmol/l 16.35  20.91 16.18  15.40 
Platelet count, 109/l 193.34  54.75 184.53  54.62 
HBV DNA, log10 IU/ml 6.82  1.97 6.16  1.86 
PDGF-BB, log10 pg/ml 4.70  0.48 4.69  0.46 
PT, s 13.44  10.62 13.28  6.49 
INR 1.21  2.32 1.14  1.39 
PDGF-BB, platelet-derived growth factor BB; BMI, body mass index; ALT, alanine ami
gamma-glutamyl transpeptidase; TBil, total bilirubin; HBV, hepatitis B virus; PT, proth
a Results are presented as the mean  standard deviation, or n (%).
Table 4
Multiple ordered logistic regression analysis with Ishak ﬁbrosis stages as the dependen
Fibrosis stage Multiple analysis PDGF-BB (log pg/ml
F0–1 OR (95% CI) 2.130 (0.886–5.124
p-Value 0.091 
b 0.751 
F2 OR (95% CI) 2.587 (1.090–6.139
p-Value 0.031 
b 0.951 
F3 OR (95% CI) 3.249 (1.261–8.374
p-Value 0.015 
b 1.178 
PDGF-BB, platelet-derived growth factor BB; GGT, gamma-glutamyl transpeptidase; OR
a F4 as the reference category.equal efﬁciency to APRI (0.823) and the FIB-4 score (0.822) for
signiﬁcant ﬁbrosis in patients with normal ALT (Table 5).
Furthermore, using cut-off values of 1.05, 1.28, and 1.43 produced
a sensitivity of 0.95, 0.76, and 0.52, a speciﬁcity of 0.29, 0.83, and
0.95, a PPV of 0.30, 0.90, and 0.79, an NPV of 0.96, 0.60, and 0.86, a
positive likelihood ratio of 1.31, 4.40, and 11.25, and a negative
likelihood ratio of 4.17, 3.43, and 1.98, respectively. Using cut-offs
of 1.05 and 1.43 for the absence or presence of signiﬁcant ﬁbrosis in
CHB patients with normal ALT, respectively, the correct diagnosis
rate was up to 88.4%; however, patients with PGT within the range
of 1.05 to 1.43 still required a liver biopsy for further ﬁbrosis
assessment. Additionally, in the 303 patients with ALT levels lower
than two times the upper limit of normal (2  ULN), the AUROC of
the PGT score for F2 was 0.727, whereas it was 0.775 for F3 and
0.746 for F4. The existing APRI and FIB-4 scores showed AUROCs
of 0.748, 0.788, and 0.757 (APRI) and 0.656, 0.734, and 0.678 (FIB-
4) for mild, signiﬁcant, and severe ﬁbrosis, respectively, in patients
with ALT levels lower than 2  ULN (data not shown).
4. Discussion
PDGF comprises a series of secretory growth factors that play
important roles in the pathogenesis of ﬁbrosis. PDGF-BB activates
HSCs and induces portal ﬁbroblast proliferation, in addition to
regulating chemotaxis, cell migration, and cell survival.15 In the
liver, PDGF-BB levels have been shown to correlate with the
incidence of hepatic ﬁbrosis of different etiologies.13,18,19 However,
although numerous studies have evaluated PDGF-BB levels in liver
tissue samples obtained from HBV-infected patients and in animal
models, few studies have assessed serum PDGF-BB levels in
patients with CHB infections. The current study, performed in alysisa
F3 F4 p-Value
12 (13.3%) 8 (10.4%) <0.001
65 (72.2%) 67 (87%) 0.139
23.45  2.92 23.90  2.89 0.052
120.43  179.99 123.63  195.14 0.001
89.82  130.16 80.51  110.99 <0.001
90.64  35.33 94.53  29.70 <0.001
69.19  62.72 85.69  80.67 <0.001
43.33  5.87 42.67  5.99 0.003
17.00  9.68 19.17  10.17 0.001
153.33  48.91 140.62  50.39 <0.001
6.01  1.66 5.74  1.97 0.001
4.56  0.51 4.31  0.72 0.002
13.39  1.49 13.28  1.99 0.997
1.08  0.14 1.10  0.14 0.903
notransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT,
rombin time; INR; international normalized ratio.
t variablea
) Platelet count (109/l) GGT (U/l)
) 1.014 (1.002–1.026) 0.982 (0.973–0.991)
0.019 <0.001
0.014 0.018
) 1.010 (0.999–1.022) 0.992 (0.986–0.999)
0.076 0.028
0.01 0.008
) 0.993 (0.981–1.005) 0.998 (0.992–1.005)
0.261 0.656
0.007 0.002
, odds ratio; CI, conﬁdence interval.
Table 5
Receiver operating characteristic curve analysis of ﬁbrosis scores in different ﬁbrosis groups; AUROC (95% conﬁdence interval)
F0–1 vs. F2–6 F0–2 vs. F3–6 F0–3 vs. F4–6
For all patients (n = 465)
PDGF-BB 0.560 (0.502–0.617) 0.609 (0.556–0.662) 0.574 (0.505–0.644)
PGT score 0.711 (0.661–0.761) 0.746 (0.699–0.793) 0.755 (0.699–0.812)
APRI 0.724 (0.673–0.776) 0.697 (0.649–0.745) 0.684 (0.625–0.743)
FIB-4 0.648 (0.596–0.700) 0.694 (0.643–0.746) 0.654 (0.587–0.721)
For patients with normal ALT levels (n = 122)
PDGF-BB 0.605 (0.502–0.708) 0.661 (0.556–0.765) 0.549 (0.407–0.691)
PGT score 0.756 (0.668–0.845) 0.831 (0.738–0.925) 0.877 (0.794–0.960)
APRI 0.806 (0.728–0.883) 0.823 (0.732–0.914) 0.884 (0.811–0.957)
FIB-4 0.790 (0.708–0.870) 0.822 (0.740–0.903) 0.791 (0.699–0.882)
AUROC, area under the receiver operating characteristics curve; PDGF-BB, platelet-derived growth factor BB; PGT score, combination of PDGF-BB, gamma-
glutamyl transpeptidase, and platelet levels; APRI, aspartate aminotransferase-to-platelet ratio; FIB-4, ﬁbrosis index based on four factors; ALT, alanine
aminotransferase.
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ﬁbrosis stage increased (p = 0.003, Spearman’s rho = 0.16).
PDGF-BB is typically secreted by a variety of cell types,
including PLTs, ﬁbroblasts, endothelial cells, mast cells, and
macrophages.20 There is currently no clear evidence to indicate
the types of cells that predominantly express PDGF-BB during
hepatic ﬁbrogenesis. In earlier studies, Pinzani et al.19 and Ikura
et al.13 reported that PDGF-BB mRNA expression was markedly
elevated in cirrhotic liver tissues and that inﬁltrating macrophages
and HSCs are the primary sources of PDGF-BB via autocrine or
paracrine signaling. From the intrahepatic perspective, PDGF-
mediated signaling through PDGFRa or PDGFb receptors strongly
promotes HSC activation and induces phenotypic changes,
followed by collagen deposition and ﬁbrogenesis.21 From the
extrahepatic perspective, there are additional underlying cellular
events that induce the progression of ﬁbrotic disease. Notably, PLTs
are a rich source of PDGF proteins.22 Yoshida et al. recently
conﬁrmed that serum PDGF-BB is largely supplied to damaged
liver tissues via PLTs, rather than being produced by resident cells,
such as macrophages and activated cholangiocytes.18 These
ﬁndings were demonstrated in anti-PLT experiments in which
reduced serum and hepatic PDGF-BB levels corresponded to
signiﬁcantly attenuated ﬁbrosis status. The destruction of PLTs is a
common complication of chronic liver disease, especially in the
case of cirrhosis, and this destruction has been attributed to
multiple mechanisms.23
In the current study, serum PLT levels were signiﬁcantly
decreased in all HBV-infected patients assessed with ﬁbrosis
stage 2 (data not shown), and the serum PLT level was highly
correlated with the serum PDGF-BB level (Table 2). These results
are consistent with those reported previously.18,24 The results
may be explained by the hypothesis that decreases in PLT levels
profoundly affect extrahepatic PDGF-BB levels in patients with
liver ﬁbrogenesis caused by HBV infection, despite intrahepatic
PDGF being expressed by pro-ﬁbrogenic cells, including macro-
phages and HSCs in the injured liver. Further studies are
necessary to explore the mechanisms underlying these relation-
ships.
Serum ALT is the most widely used index to screen for and
assess injury status in patients with liver disease. However, the
connection between ALT and degree of hepatic injury is not strong,
as exempliﬁed by the common observation that a portion of
chronic HBV-infected patients, who are categorized as chronic HBV
carriers by current diagnostic standards, have serious liver injury
despite normal ALT levels.25
According to current guidelines, CHB patients with signiﬁcant
ﬁbrosis (Ishak score F3) should be treated immediately.26 In the
current study, 26.2% of the 122 patients enrolled with normal ALT
levels had signiﬁcant ﬁbrosis. Thus, serum PDGF-BB levels were
compared with the ﬁbrosis stages in patients with normal ALT. Inall of the patients evaluated with normal ALT, serum PDGF-BB
correlated signiﬁcantly with ﬁbrosis stage (F0–2 vs. F3, p = 0.007)
(Figure 1B). Therefore, the data suggest that PDGF-BB could be a
potential biomarker for the assessment of ﬁbrosis stage in patients
with CHB.
In recent years, several serum biomarkers and marker panels
have been developed to predict hepatic ﬁbrosis. Two commonly
used scores, APRI and FIB-4, have successfully predicted hepatic
ﬁbrosis in large cohorts of HCV-infected patients.27,28 Numerous
reports have also indicated that APRI and FIB-4 scores are useful in
clinical practice for assessing liver ﬁbrosis in CHB patients.9,10,29
The present study showed that the combined evaluation of serum
PDGF-BB, GGT, and PLT levels, via PGT score, produced signiﬁcantly
higher AUROCs than serum PDGF-BB alone for diagnosing the
different stages of ﬁbrosis. APRI and FIB-4 scores were employed to
evaluate signiﬁcant ﬁbrosis and showed AUROCs of 0.823 and
0.821 in patients with normal ALT levels. Compared to these scores,
the use of the PGT score produced similar AUROCs in diagnosing
signiﬁcant ﬁbrosis in patients with normal ALT levels. Moreover,
88.4% of patients would be correctly diagnosed using the cut-offs of
1.05 and 1.43 for the absence or presence of signiﬁcant ﬁbrosis,
respectively, in CHB patients with normal ALT levels.
This study had some limitations. First, it was a cross-sectional
study and the authors did not have access to longitudinal data to
verify the results. Second, a mechanism for investigating cellular
sources of PDGF-BB expression in liver tissue is lacking. Finally,
serum PDGF-BB and the PGT score provide robust data, especially
in total CHB patients. Additional studies are needed to investigate
the use of PDGF-BB and the PGT score for staging liver ﬁbrosis in
combination with other ﬁbrosis markers. Therefore, future
prospective studies should be performed to reach a higher
diagnostic accuracy, especially in differentiating signiﬁcant/severe
ﬁbrosis from moderate stages of ﬁbrosis.
In conclusion, serum PDGF-BB levels decreased remarkably
during ﬁbrogenesis and these could be used as a non-invasive
biomarker of ﬁbrosis stage in patients with CHB. Furthermore, the
PGT score showed equal efﬁciency to other ﬁbrosis scores in
diagnosing signiﬁcant ﬁbrosis in patients with normal ALT.
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